Clinical Trial Update: Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN [Phase 2]

View source ↗

Summary

Clinical trial update on the safety and tolerability of durvalumab combined with radiotherapy for head and neck squamous cell carcinoma (Phase 2), currently act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Groupe Oncologie Radiotherapie Tete et Cou | Conditions: HNSCC | Phase 2 | Status: ACTIVE_NOT_RECRUITING